Sanofi's R&D will lead to a 50% increase in Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi's history. The company's commitment to R&D will also support an ...

Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand, and focusing on the discovery, design, and clinical ...

While early-stage, the Adagene deal is another example of Sanofi's determination to bolster its R&D pipeline via a string of deals, including a $5.2 billion, strategic-level alliance with UK ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

pharmaphorum's Hannah Blake catches up with Dr Tal Zaks from Sanofi Oncology to see where the global pharma company's oncology pipeline is heading, the unique partnerships that have helped Sanofi ...

Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand, and focusing on the discovery, design ...

Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand, and focusing on the discovery, design, and clinical ...